Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Current Allergy and Asthma Reports
Published in: Current Allergy and Asthma Reports 5/2020

01-05-2020 | Food Allergy | Food Allergy (E Kim, Section Editor)

Peanut Oral Immunotherapy: a Current Perspective

Authors: Meera Patrawala, Jennifer Shih, Gerald Lee, Brian Vickery

Published in: Current Allergy and Asthma Reports | Issue 5/2020

Login to get access

Abstract

Purpose of the Review

Peanut oral immunotherapy (OIT) is one of the most studied experimental therapies for food allergy. With the recently FDA-approved peanut product, Palforzia, the goal of this article is to review the most recent data from clinical trials, discuss recent trends, and anticipate future developments.

Recent Findings

The latest research suggests that peanut OIT could be a promising option for peanut-allergic patients, with the majority of participants in research studies achieving the primary efficacy endpoint of desensitization, as well as sustained unresponsiveness in select populations. Some studies also showed improvements in food allergy-related quality of life. However, peanut OIT is not without risk or side effects, including potentially serious allergic reactions.

Summary

Future research will need to evaluate the short- and long-term effectiveness of the therapy in the real-world setting, predictors of important treatment outcomes, and the use of adjunctive therapies that may mitigate some of these allergic reactions.
Literature
1.
Sicherer SH, Sampson HA. Food allergy: epidemiology, pathogenesis, diagnosis, and treatment. J Allergy Clin Immunol. 2014;133(2):291–307 quiz 8.CrossRef
2.
Boyce JA, Assa'ad A, Burks AW, Jones SM, Sampson HA, Wood RA, Plaut M, Cooper SF, Fenton MJ, Arshad SH, Bahna SL, Beck LA, Byrd-Bredbenner C, Camargo CA Jr, Eichenfield L, Furuta GT, Hanifin JM, Jones C, Kraft M, Levy BD, Lieberman P, Luccioli S, McCall K, Schneider LC, Simon RA, Simons FE, Teach SJ, Yawn BP, Schwaninger JM, NIAID-Sponsored Expert Panel. Guidelines for the diagnosis and management of food allergy in the United States: summary of the NIAID-sponsored expert panel report. J Allergy Clin Immunol 2010;126(6):1105–1118.
3.
Sampson HA, Aceves S, Bock SA, James J, Jones S, Lang D, Nadeau K, Nowak-Wegrzyn A, Oppenheimer J, Perry TT, Randolph C, Sicherer SH, Simon RA, Vickery BP, Wood R, Joint Task Force on Practice Parameters, Bernstein D, Blessing-Moore J, Khan D, Lang D, Nicklas R, Oppenheimer J, Portnoy J, Randolph C, Schuller D, Spector S, Tilles SA, Wallace D, Practice Parameter Workgroup, Sampson HA, Aceves S, Bock SA, James J, Jones S, Lang D, Nadeau K, Nowak-Wegrzyn A, Oppenheimer J, Perry TT, Randolph C, Sicherer SH, Simon RA, Vickery BP, Wood R Food allergy: a practice parameter update-2014. J Allergy Clin Immunol 2014;134(5):1016–1025 e43.
4.
Hofmann AM, Scurlock AM, Jones SM, Palmer KP, Lokhnygina Y, Steele PH, et al. Safety of a peanut oral immunotherapy protocol in children with peanut allergy. J Allergy Clin Immunol. 2009;124(2):286–91 e1–6.CrossRef
5.
Burbank AJ, Sood P, Vickery BP, Wood RA. Oral immunotherapy for food allergy. Immunol Allergy Clin N Am. 2016;36(1):55–69.CrossRef
6.
Wasserman RL, Hague AR, Pence DM, Sugerman RW, Silvers SK, Rolen JG, et al. Real-world experience with peanut oral immunotherapy: lessons learned from 270 patients. J Allergy Clin Immunol Pract. 2019;7(2):418–26 e4.CrossRef
7.
•• Chu DK, Wood RA, French S, Fiocchi A, Jordana M, Waserman S, et al. Oral immunotherapy for peanut allergy (PACE): a systematic review and meta-analysis of efficacy and safety. Lancet. 2019;393(10187):2222–32 Comment: Demonstrated moderate to high certainty that OIT treatment is very likely to result in desensitization but also increases the relative risk of allergic reactions compared to avoidance.CrossRef
8.
•• Investigators PGoC, Vickery BP, Vereda A, Casale TB, Beyer K, du Toit G, et al. AR101 oral immunotherapy for peanut allergy. N Engl J Med. 2018;379(21):1991–2001 Comment: This Phase 3 trial of AR101 was the largest DBRPC peanut OIT trial to date.CrossRef
9.
• Blumchen K, Trendelenburg V, Ahrens F, Gruebl A, Hamelmann E, Hansen G, et al. Efficacy, safety, and quality of life in a multicenter, randomized, placebo-controlled trial of low-dose peanut oral immunotherapy in children with peanut allergy. J Allergy Clin Immunol Pract. 2019;7(2):479–91 e10. Comment: This multicenter RCT demonstrated that a low-dose regimen with very gradual up-dosing improved safety of peanut OIT, protection against real world accidents, and improved QOL in peanut-allergic patients.CrossRef
10.
Peters RL, Allen KJ, Dharmage SC, Koplin JJ, Dang T, Tilbrook KP, et al. Natural history of peanut allergy and predictors of resolution in the first 4 years of life: a population-based assessment. J Allergy Clin Immunol. 2015;135(5):1257–66 e1–2.CrossRef
11.
Vickery BP, Berglund JP, Burk CM, Fine JP, Kim EH, Kim JI, et al. Early oral immunotherapy in peanut-allergic preschool children is safe and highly effective. J Allergy Clin Immunol. 2017;139(1):173–81 e8.CrossRef
12.
Soller L, Abrams EM, Carr S, Kapur S, Rex GA, Leo S, et al. First real-world safety analysis of preschool peanut oral immunotherapy. J Allergy Clin Immunol Pract. 2019.
13.
Fauquert JL, Michaud E, Pereira B, Bernard L, Gourdon-Dubois N, Rouzaire PO, et al. Peanut gastrointestinal delivery oral immunotherapy in adolescents: results of the build-up phase of a randomized, double-blind, placebo-controlled trial (PITA study). Clin Exp Allergy. 2018;48(7):862–74.CrossRef
14.
• Tang ML, Ponsonby AL, Orsini F, Tey D, Robinson M, Su EL, et al. Administration of a probiotic with peanut oral immunotherapy: a randomized trial. J allergy Clin Immunol. 2015;135(3):737–44 e8. Comment: Showed that a probiotic-containing peanut OIT formulation in late-stage clinical development was well tolerated and led to sustained clinical benefits.CrossRef
15.
• Hsiao KC, Ponsonby AL, Axelrad C, Pitkin S, Tang MLK, Team PS. Long-term clinical and immunological effects of probiotic and peanut oral immunotherapy after treatment cessation: 4-year follow-up of a randomised, double-blind, placebo-controlled trial. Lancet Child Adolesc Health. 2017;1(2):97–105 Comment: Showed that a probiotic-containing peanut OIT formulation in late-stage clinical development was well tolerated and led to sustained clinical benefits.CrossRef
16.
• Duca B, Patel N, Turner PJ. GRADE-ing the benefit/risk equation in food immunotherapy. Curr Allergy Asthma Rep. 2019;19(6):30 Comment: A systematic review that comprehensively discusses the current knowledge gaps in the field and proposes a framework to understand the benefit/risk of the treatment.CrossRef
17.
Chong KW, Turner PJ. Food allergy desensitisation: a hard nut to crack? Arch dis child. 2019.
18.
Dunn Galvin A, McMahon S, Ponsonby AL, Hsiao KC, Tang MLK, Team Ps. The longitudinal impact of probiotic and peanut oral immunotherapy on health-related quality of life. Allergy. 2018;73(3):560–568.
19.
Reier-Nilsen T, Carlsen KCL, Michelsen MM, Drottning S, Carlsen KH, Zhang C, et al. Parent and child perception of quality of life in a randomized controlled peanut oral immunotherapy trial. Pediatr Allergy Immunol. 2019.
20.
Virkud YV, Burks AW, Steele PH, Edwards LJ, Berglund JP, Jones SM, et al. Novel baseline predictors of adverse events during oral immunotherapy in children with peanut allergy. J Allergy Clin Immunol. 2017;139(3):882–8 e5.CrossRef
21.
Kukkonen AK, Uotila R, Malmberg LP, Pelkonen AS, Makela MJ. Double-blind placebo-controlled challenge showed that peanut oral immunotherapy was effective for severe allergy without negative effects on airway inflammation. Acta Paediatr. 2017;106(2):274–81.CrossRef
22.
•• Chinthrajah RS, Purington N, Andorf S, Long A, O'Laughlin KL, Lyu SC, et al. Sustained outcomes in oral immunotherapy for peanut allergy (POISED study): a large, randomised, double-blind, placebo-controlled, phase 2 study. Lancet. 2019; Comment: The largest trial to prospectively address the rate of clinical remission after treatment with peanut OIT using three different regimens.
23.
•• Patil SU, Steinbrecher J, Calatroni A, Smith N, Ma A, Ruiter B, et al. Early decrease in basophil sensitivity to Ara h 2 precedes sustained unresponsiveness after peanut oral immunotherapy. J Allergy Clin Immunol. 2019; Comment: Demonstrated that basophil activation testing three months into treatment, and at the time of treatment cessation, predicts clinical remission, suggesting its use as a biomarker.
24.
Howe LC, Leibowitz KA, Perry MA, Bitler JM, Block W, Kaptchuk TJ, et al. Changing patient mindsets about non-life-threatening symptoms during oral immunotherapy: a randomized clinical trial. J Allergy Clin Immunol Pract. 2019;7(5):1550–9.CrossRef
25.
MacGinnitie AJ, Rachid R, Gragg H, Little SV, Lakin P, Cianferoni A, et al. Omalizumab facilitates rapid oral desensitization for peanut allergy. J Allergy Clin Immunol. 2017;139(3):873–81 e8.CrossRef
26.
Blaiss MS, Tilles S, Petroni D, Zigmont E, Cassese M, Kwak B, et al. Current management and use of oral immunotherapy in the United States for patients with peanut allergy. Allergy Asthma Proc. 2019.
27.
Wasserman RL, Jones DH, Windom HH. Oral immunotherapy for food allergy: the FAST perspective. Ann Allergy Asthma Immunol. 2018;121(3):272–5.CrossRef
28.
• Wasserman RL, Jones DH, Windom HH, Meeting F. Reaching for best practices in food oral immunotherapy: report on the second annual Food Allergy Support Team meeting. Ann Allergy Asthma Immunol. 2019;123(2):129–30 e3. Comment: The leading clinical practitioners of OIT (not only for peanut) review their practices, giving some insights into the real-world experience of treating patients.CrossRef
29.
Bird JA, Feldman M, Arneson A, Dougherty I, Brown LS, Burk CM, et al. Modified peanut oral immunotherapy protocol safely and effectively induces desensitization. J Allergy Clin Immunol Pract. 2015;3(3):433–5 e1–3.CrossRef
30.
Narisety SD, Frischmeyer-Guerrerio PA, Keet CA, Gorelik M, Schroeder J, Hamilton RG, et al. A randomized, double-blind, placebo-controlled pilot study of sublingual versus oral immunotherapy for the treatment of peanut allergy. J Allergy Clin Immunol. 2015;135(5):1275–82 e1–6.CrossRef
31.
Vickery BP, Scurlock AM, Kulis M, Steele PH, Kamilaris J, Berglund JP, et al. Sustained unresponsiveness to peanut in subjects who have completed peanut oral immunotherapy. J Allergy Clin Immunol. 2014;133(2):468–75.CrossRef
32.
Anagnostou K, Islam S, King Y, Foley L, Pasea L, Bond S, et al. Assessing the efficacy of oral immunotherapy for the desensitisation of peanut allergy in children (STOP II): a phase 2 randomised controlled trial. Lancet. 2014;383(9925):1297–304.CrossRef
Metadata
Title
Peanut Oral Immunotherapy: a Current Perspective
Authors
Meera Patrawala
Jennifer Shih
Gerald Lee
Brian Vickery
Publication date
01-05-2020
Publisher
Springer US
Keyword
Food Allergy
Published in
Current Allergy and Asthma Reports / Issue 5/2020
Print ISSN: 1529-7322
Electronic ISSN: 1534-6315
DOI
https://doi.org/10.1007/s11882-020-00908-6